A T cell redirecting bispecific protein consisting of an affinity enhanced T cell receptor fused to an anti-CD3 molecule that engages gp100 presented by major histocompatibility complex class I HLA-A 02:01 on tumor cells.

For the treatment of metastatic uveal melanoma in patients  positive for HLA-A02:01 with metastatic or unrespectable uveal melanoma.

It demonstrated superior overall survival and progression free survival compared with it Pembrolizumab, Ipilimumab, or dacarbazine.

Objective response rate was only 9% but the disease control rate was 46%, suggesting clinical benefit without substantial to reduction on imaging studies.

Associated with cytokine release syndrome, rash and requires in patient  monitoring for the first three doses.

In a three-year efficacy and safety trial patients were treated withTebentafusp versus Pembrolizumab, ipilimumab or dacarbazine control.

At three years, 27% in theTebentafusp group survived and 18% in the control group.

Tebentafusp toxicity included rash and 83%, pyrexia, 76%, pus in 70%, and hypotension and 38%: only 2% of the treatment group discontinued therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *